Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

5.0%

1 terminated/withdrawn out of 20 trials

Success Rate

95.0%

+8.5% vs industry average

Late-Stage Pipeline

35%

7 trials in Phase 3/4

Results Transparency

53%

10 of 19 completed trials have results

Key Signals

10 with results

Enrollment Performance

Analytics

Phase 2

6(31.6%)

Phase 1

5(26.3%)

Phase 3

4(21.1%)

Phase 4

3(15.8%)

N/A

1(5.3%)

19Total

Phase 2(6)

Phase 1(5)

Phase 3(4)

Phase 4(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials

NCT00867048Phase 4Completed

Strategic Timing of Antiretroviral Treatment

Role: collaborator

NCT00758043Phase 3Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Role: collaborator

NCT00255801Phase 2Completed

Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma

Role: collaborator

NCT00756730Phase 4Completed

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

Role: collaborator

NCT01217359Phase 1Completed

Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling

Role: collaborator

NCT00303108Phase 2Completed

Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer

Role: collaborator

NCT01369056Not ApplicableCompleted

HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence

Role: collaborator

NCT00677300Phase 4Completed

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

Role: collaborator

NCT00627926Phase 3Completed

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Role: collaborator

NCT00919854Phase 2Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Role: collaborator

NCT00916474Completed

Virology Follow up Study in Subjects Previously Treated With Telaprevir

Role: collaborator

NCT00703118Phase 3Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Role: collaborator

NCT00983853Phase 2Completed

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Role: collaborator

NCT00421551Phase 3Completed

Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

Role: collaborator

NCT00915655Phase 2Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

Role: collaborator

NCT00855088Phase 1Completed

Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue

Role: collaborator

NCT01038167Phase 1Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Role: collaborator

NCT00332995Phase 1Completed

Safety and Feasibility Study of Dapivirine (TMC120) Vaginal Ring in Belgium

Role: collaborator

NCT00700284Phase 1Completed

Feasibility Study of a Vaginal Ring for Delivery of TMC120 (Dapivirine)

Role: collaborator

NCT00120198Phase 2Terminated

Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Role: collaborator

All 20 trials loaded